This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q80.4 / Special Copayment Reduction: V300 / Re-approval cycle: 5 years |
| B. Synonyms | None |
| C. Adult onset | Congenital disease presenting at or shortly after birth; in surviving patients, severe ichthyosis persists into adulthood |
| 1. History | First described by Reverend Charleston in 1750; ABCA12 mutations identified in the late 20th century |
| 2. Causes | Loss-of-function variants in the ABCA12 gene cause defective lamellar body lipid secretion and failure to form the cornified barrier |
| 3. Genetics | Autosomal recessive (AR); ABCA12 gene (2q34); various missense, nonsense, and splice-site mutations |
| 4. General epidemiology | Incidence about 1/500,000 births; about 200 cases reported worldwide; increased frequency in consanguineous populations |
| 5. Pathophysiology | ABCA12 deficiency → defective ceramide transport into lamellar bodies → loss of the stratum corneum lipid barrier → severe transepidermal water loss |
| 6. Symptoms | At birth, thick plate-like scales with fissures over the whole body, ectropion, absent auricles, and systemic complications such as respiratory failure |
| 7. Signs | Diamond-shaped fissured plates, ectropion and eclabium, poorly developed nose/ears, restricted movement of fingers and toes |
| 8. Screening | Prenatal ultrasound (fetal skin thickening, polyhydramnios), ABCA12 genetic testing after amniocentesis or chorionic villus sampling |
| 9. Diagnosis | Confirmed by clinical findings + skin biopsy (electron microscopy) + ABCA12 molecular genetic testing |
| 10. Treatment | High-humidity incubator, intensive moisturizing, retinoids (acitretin), infection prevention, respiratory support |
| 11. Prognosis | Traditionally fatal in the neonatal period; survival increased with modern intensive care, but survivors have reduced quality of life due to severe ichthyosis |
| 12. Prevention | Genetic counseling, carrier testing, prenatal molecular genetic diagnosis; avoidance of consanguineous marriage recommended |
| 13. References | Rajpopat S et al. (2011) Harlequin ichthyosis: a review of clinical and molecular findings and 9 other papers |
Harlequin fetus is one of the most dramatic congenital skin diseases in recorded human history, with origins dating back to the early 18th century. The first written record is the description by Reverend Oliver Hart, in his diary, of the clinical findings of an infant born in Charleston, South Carolina, USA, in 1750 who died a few days after birth; this is known as the first case entered in the medical literature. The description depicts thick, armor-like fissures of the stratum corneum covering the whole body, and it was reported that rhombus- and triangle-shaped plates covered the entire skin surface.
The disease name "Harlequin" comes from the costume of the clown character in the Italian Commedia dell'arte, a colorful costume with a diamond pattern. The name was given because the fissure pattern of the newborn's skin resembles this diamond pattern. Sporadic case reports continued through the 19th and early 20th centuries, but the mechanism of the disease remained completely unknown.
With the introduction of electron microscopy in the mid-20th century, structural abnormalities of the stratum corneum began to be identified, and defects of lamellar bodies were revealed as the core pathology. In the 1980s, research on the role of the organelles involved in forming the stratum corneum lipid barrier became active, laying the foundation for a molecular understanding of the pathogenesis of harlequin fetus.
The decisive advance was a 2005 study by Kelsell et al. published in Nature Genetics, which first identified mutations in the ABCA12 gene as the cause of harlequin fetus. ABCA12 encodes ATP-binding cassette transporter subfamily A member 12 and plays an essential role in transporting lipids such as ceramide into the lamellar bodies of keratinocytes. This discovery clarified the molecular link between harlequin fetus and lamellar ichthyosis and later became the basis for prenatal diagnosis and molecular genetic counseling.
Since the 2000s, as advances in intensive care medicine and the introduction of retinoid therapy improved neonatal survival, reports on the long-term clinical course of patients who survived harlequin fetus into adulthood began to accumulate. In 2011, Rajpopat et al. analyzed 45 surviving patients and systematically described survival potential and long-term prognosis in the modern treatment setting. To date, more than 200 cases have been reported worldwide, and research continues at the intersection of molecular genetics and dermatology.
The fundamental cause of harlequin fetus is defective lipid secretion from keratinocyte lamellar bodies (lamellar granule/body) due to loss-of-function mutations in the ABCA12 gene. The ABCA12 protein is a lipid transporter located in the lamellar body membrane and is responsible for actively transporting lipids such as glucosylceramide and ceramide from the lamellar body lumen into the intercellular space.
During normal formation of the stratum corneum, keratinocytes of the stratum granulosum secrete lamellar bodies at the cell surface, and the lipid molecules released from them form lamellar structures in the intercellular space, constituting a strong permeability barrier. This barrier consists of ceramide, cholesterol, and fatty acids, and ceramide in particular is the key component for structural integrity.
When ABCA12 function is lost, the packaging of lipids, including ceramide, into lamellar bodies and their secretion into the intercellular space are severely impaired. As a result, lipid lamellar structures cannot form in the intercellular spaces of the stratum corneum, and the skin permeability barrier collapses completely. Consequently, during fetal development the stratum corneum fails to shed normally and forms an abnormally thick plate-like structure.
In addition, ABCA12 plays complex roles in keratinocyte differentiation and epidermal lipid homeostasis, and some mutations are known to cause loss of function through mechanisms such as protein misfolding, intracellular retention, and degradation. The degree of residual protein function varies with the type of mutation (truncating vs. missense), and this is an important factor determining the phenotypic spectrum between harlequin fetus and the milder lamellar ichthyosis type 2.
Environmental factors or isolated mutations in other genes are not direct causes of harlequin fetus. However, the theoretical possibility has been raised that genetic background, polymorphisms in regulatory genes, and similar factors may contribute to variation in clinical severity.
Harlequin fetus follows an autosomal recessive (AR) mode of inheritance, and the causative gene is ABCA12, located on chromosome 2q34. ABCA12 consists of 52 exons and encodes a large transmembrane protein of 5,592 amino acids. This protein has two transmembrane domains (TMD) and two ATP-binding cassette (ABC) domains.
Reported ABCA12 mutations include various forms, such as missense mutations, nonsense mutations, frameshift mutations, splice-site mutations, and large exon deletions. In harlequin fetus, truncating mutations (premature termination codons, frameshift, nonsense, etc.) that abolish protein expression altogether or completely inactivate the protein functionally are mainly observed. In contrast, missense mutations that allow partial function are more common in the milder phenotype, lamellar ichthyosis type 2.
Compound heterozygous mutations are not uncommon; in this case, a different mutation is found on each allele. The parents of a patient with harlequin fetus are each asymptomatic carriers of one mutant allele, and 25% of the children born to them develop the disease.
In certain ethnic groups, specific mutations are observed at high frequency because of a founder effect. Incidence is significantly higher in populations with consanguineous marriage, and homozygous mutations are observed more often than compound heterozygous ones. For prenatal molecular genetic diagnosis, the mutation must first be identified in the index patient in the family.
Genotype-phenotype correlation studies on the relationship between each domain of the ABCA12 protein and clinical severity are underway, and it is becoming increasingly clear that whether residual function is preserved, depending on the location or type of a specific mutation, is the key factor determining phenotype.
Harlequin fetus is an extremely rare disease with a worldwide frequency of about 1/500,000 births. The total number of cases reported in the literature was about 200–250 as of the early 2020s, and there are limits to determining the exact prevalence. This means that, because of the high neonatal mortality, a substantial number of cases die before diagnosis or go unrecorded.
There is no sex bias, and it occurs with equal frequency in boys and girls. It has been reported in all racial and ethnic groups, but a relatively high frequency is observed in populations where consanguineous marriage is common (the Middle East, parts of South Asia, etc.). This results from the autosomal recessive mode of inheritance and increased carrier frequency.
Reports from East Asia, including Korea, are rare, but this may reflect differences in diagnosis and publication rates. In Korea, a small number of cases have been reported in journals, and surviving cases are gradually increasing with advances in neonatal intensive care.
No direct association with maternal age, mode of delivery, region, or economic level has been clearly established. However, consanguinity and family history are the strongest epidemiological risk factors. As prenatal diagnosis rates have improved with the spread of molecular genetic technology, preventive screening in high-risk families has become possible. The carrier frequency in the general population is estimated at about 1/300–1/500, but accurate data are lacking.
The pathophysiology of harlequin fetus is understood as a complex cascade starting from a single core mechanism: impaired formation of the stratum corneum lipid barrier due to loss of ABCA12 protein function. During normal development of fetal skin, stratum corneum formation begins around 20 weeks of gestation, and lamellar bodies within stratum granulosum cells are secreted extracellularly to form intercellular lipid lamellae.
In ABCA12 deficiency, the packaging and transport of glucosylceramide in lamellar bodies are defective, so ceramide generation and the formation of intercellular lipid lamellae do not occur from the secreted lamellar bodies. As a result, the epidermal permeability barrier collapses completely, and an abnormally thick stratum corneum is produced even amid continuous hydration of the keratin by amniotic fluid in utero.
Desquamation of fetal skin also does not proceed normally. Normally, in the outer stratum corneum, serine proteases of the kallikrein family break down the bonds between corneocytes to mediate shedding, and this process also depends on the intercellular lipid environment. Therefore, in ABCA12 deficiency, serine protease activity is suppressed, and abnormal accumulation of the stratum corneum is accelerated.
As a result, at birth the entire skin is covered with a plate-like armor-like carapace of keratin up to several centimeters thick; this carapace severely reduces skin extensibility, causing mechanical restriction. On the face it causes ectropion and eclabium, and it impedes chest wall movement, causing respiratory failure. In addition, transepidermal water loss (TEWL) due to the loss of the barrier is extreme, leading to fluid loss and failure of thermoregulation.
In addition, loss of defense against skin infection, systemic inflammatory responses, impaired nutrient absorption, and other problems occur together and are the main causes of the fatal course in the neonatal period.
The clinical symptoms of harlequin fetus are immediately obvious at birth, and the formation of extremely thick plates over the entire skin is the most prominent finding. The plates range from several millimeters to several centimeters thick and divide the whole skin surface into diamond-shaped and polygonal blocks separated by deep red fissures. At the fissures, deep depressions resembling lacerations of the skin surface are observed.
Because of facial involvement, ectropion is almost always present, and the conjunctiva and cornea are exposed. Dry eyes, corneal damage, conjunctivitis, and similar problems arise from early on. Eclabium causes the mouth to be held wide open, making normal feeding impossible. The nose is flat or the external nose is incompletely developed, and the auricles are occluded or deformed by keratin plates.
Respiratory failure is the most immediate threat to life. The thick chest wall plates physically restrict chest expansion so that the respiratory apparatus cannot function properly, and mechanical ventilation is therefore often needed immediately after birth. Clearing airway secretions is also difficult, so the risk of aspiration pneumonia is high.
Fluid loss and impaired thermoregulation are also major problems in the neonatal period. Because of the complete absence of the normal skin barrier, transepidermal water loss is extremely severe, and without adequate fluid replacement, severe dehydration and electrolyte abnormalities occur. The risk of overheating or hypothermia also increases. Flexion contractures of the fingers and toes may develop, and free movement of the limbs is restricted.
In surviving patients, a severe skin disease in the form of ichthyosis persists throughout adulthood. Regular moisturizing and descaling care is required for life, and overheating in hot weather, infections, and restricted joint movement greatly affect quality of life.
The clinical signs at birth are so characteristic that experienced clinicians can recognize them immediately by inspection alone. The thick keratin plates covering the entire skin are yellowish-white to grayish, and deep red fissure lines divide the whole body into a lattice pattern. The fissures sometimes extend as deep as the dermis, increasing the risk of infection.
Ectropion is observed in both the upper and lower eyelids, and the everted conjunctiva appears to protrude like red beads (lagophthalmos). Together with this, eclabium makes the mouth appear fixed in a wide horizontal opening, and normal mouth closure is impossible. The upper and lower alveolar ridges and gums are exposed.
The external ear is deformed or occluded by the plates, and the nose is flat, with nostrils that may be narrowed or occluded. The limbs are often fixed in flexion, and plates between the fingers and toes can make them look like syndactyly. Abnormal development or hypoplasia of the fingernails and toenails is also observed.
In terms of vital signs, increased work of breathing (intercostal retraction, nasal flaring, use of accessory muscles) and cyanosis are observed, and temperature instability is common. In rare cases, additional malformations such as microcephaly and limb shortening have also been reported.
Signs in surviving patients as they grow include coarse generalized scale, scarring alopecia, heat intolerance, hyperhidrosis or anhidrosis (anhidrosis/hypohidrosis), and recurrent secondary skin infections. Ophthalmologically, even if ectropion is corrected, exposure keratitis, corneal opacity, and visual impairment may remain as long-term complications.
Screening for harlequin fetus relies mainly on prenatal diagnosis based on family history. The standard approach is to perform prenatal molecular genetic testing from early pregnancy for couples who have previously had an affected child or who have been identified as ABCA12 carriers.
Prenatal ultrasound can be used as a screening tool, but its sensitivity is limited. From mid-pregnancy onward, fetal skin thickening, a fixed open mouth, open eyes, auricular deformity, and flexed limb postures may be seen on ultrasound. However, these findings may be nonspecific or subtle, so confirmation by ultrasound alone is difficult. Some cases are accompanied by polyhydramnios, which is understood to result from difficulty swallowing amniotic fluid due to abnormal fetal oral function.
When there is a family history, ABCA12 molecular genetic testing is performed on fetal cells obtained by first-trimester chorionic villus sampling (CVS, 10–13 weeks) or second-trimester amniocentesis (15–20 weeks). If the causative mutation has been identified in the index patient or both parents, targeted mutation detection is possible; if not, next-generation sequencing (NGS) is applied.
Preimplantation genetic diagnosis (PGD) is also technically possible and can be offered as an option to high-risk couples undergoing in vitro fertilization. Newborn screening of the general population is not currently performed, and because clinical symptoms are already obvious at birth, the need for newborn screening is limited.
The diagnosis of harlequin fetus is based on characteristic clinical findings and confirmed by skin biopsy and ABCA12 molecular genetic testing. Because the clinical findings at birth are so typical, an experienced dermatologist or neonatologist can make a clinical diagnosis immediately.
Skin biopsy and light microscopy show extremely thick orthokeratotic hyperkeratosis, thickening of the granular layer, and abnormal development of skin appendages. More important are the findings on transmission electron microscopy (TEM), which characteristically show structural abnormalities of lamellar bodies within granular layer cells (abnormal shape, abnormal contents, defective secretion) and loss of intercellular lipid lamellae. A marked reduction or complete absence of the lipid lamellar structures that normally fill the intercellular spaces is the electron microscopic gold standard for diagnosing harlequin fetus.
Molecular genetic testing is the confirmatory method that directly identifies pathogenic variants in the ABCA12 gene. It is currently performed by targeted gene panel or whole-exome sequencing (WES), and the diagnosis is confirmed when pathogenic variants are identified on both alleles. If a variant is found on only one allele, deletions and similar changes should be checked by additional methods (MLPA, copy number variant analysis, etc.).
In the differential diagnosis, congenital ichthyoses such as Netherton syndrome, nonbullous congenital ichthyosiform erythroderma (NBCIE), and lamellar ichthyosis should be considered, but the clinical severity of harlequin fetus is so much greater that clinical confusion is rare. When differentiating it from other congenital diseases with skin barrier abnormalities, TEM and molecular genetic testing play a decisive role.
Treatment of harlequin fetus is based on intensive supportive care involving a multidisciplinary team in the neonatal intensive care unit (NICU) from immediately after birth. A humidity incubator is the key environmental measure for minimizing transepidermal water loss, and the patient is managed in an incubator maintained at 50–80% relative humidity. Appropriate temperature management to maintain body temperature is provided at the same time.
Intensive topical moisturizing is needed several times a day or more. Petrolatum, liquid paraffin, ceramide-containing emollients, and similar products are applied to the whole body, promoting softening and shedding of the plates and partially supporting barrier function. Fissures are treated with sterile or moisturizing dressings to prevent infection.
Retinoid therapy is known to be the most effective systemic treatment. Acitretin or isotretinoin acts to suppress excessive keratinocyte proliferation and normalize differentiation. No protocol has been established for safe doses and administration in neonates, but many case reports indicate that early retinoid administration contributed to improved survival. With long-term use, adverse effects such as hepatotoxicity, hyperlipidemia, and teratogenicity (contraindicated in pregnancy) must be monitored.
Respiratory support often requires mechanical ventilation or non-invasive positive pressure ventilation (NPPV). Because oral intake is impossible, total parenteral nutrition (TPN) or nasogastric feeding is initially needed. Fluid and electrolyte management, infection prevention (whether to use prophylactic antibiotics is decided by institutional policy and the clinical situation), eye protection (artificial tears, eye ointment, tarsorrhaphy if needed), and ear cleaning with assessment of hearing are also part of initial treatment.
In the long term, regular keratolytic baths (emollient bath), whole-body moisturizer application, outpatient dermatology follow-up, and ongoing multidisciplinary care with ophthalmology, otolaryngology, rehabilitation medicine, and other specialties are needed. Genetic counseling and psychosocial support are also essential for both patients and families.
The prognosis of harlequin fetus varies greatly with the treatment setting. Historically the disease was known to be almost 100% fatal in the neonatal period, but survival has improved meaningfully with modern neonatal intensive care and the widespread use of retinoids. According to the 2011 analysis by Rajpopat et al., 57% of 45 patients reported since 1984 survived, and most deaths occurred within the first 3 months of life.
The main causes of death in the neonatal period are respiratory failure, sepsis, renal failure due to fluid loss, and hyperthermia. Even with appropriate NICU management, the likelihood of death in the neonatal period remains high, and intensive support during the first few weeks is decisive for survival.
Some surviving patients have lived into adulthood, but severe ichthyosis persists for life. The skin never normalizes, and continuous scaling, erythroderma, the need to apply moisturizers, and the risk of overheating in hot weather restrict daily life. Ophthalmologic complications (chronic keratitis, visual impairment), hearing impairment, growth failure, and recurrent infections remain as long-term complications.
Cognitive function and neurological development are generally normal, which makes a social life possible for survivors. However, psychosocial difficulties from disfigurement, limitations in school and work life, and family burden significantly affect quality of life. Early psychosocial intervention and long-term multidisciplinary follow-up contribute to better outcomes.
Because harlequin fetus is an autosomal recessive single-gene disease, the key to prevention lies in genetic counseling and prenatal diagnosis. In families who have had an affected child or in which ABCA12 carriers have been identified, consultation with a genetics specialist is essential from before any subsequent pregnancy. When both parents are carriers, each pregnancy has a 25% risk of being affected, so this should be fully explained and a prenatal diagnosis plan established.
For prenatal diagnosis, ABCA12 genetic testing by first-trimester chorionic villus sampling (CVS) or second-trimester amniocentesis is offered as standard. In families of an index patient, the mutation has already been identified, so targeted testing allows rapid and accurate prenatal diagnosis. Preimplantation genetic diagnosis (PGD), which selects against affected embryos through in vitro fertilization, is an alternative option for couples who do not want termination of pregnancy.
Avoidance of consanguineous marriage is a general prevention principle for autosomal recessive rare diseases and is particularly important in populations with a high carrier frequency for the disease. ABCA12 molecular genetic testing to identify carriers should be offered to individuals with a family history; carrier screening of the general population is not currently performed routinely.
Enhanced prenatal ultrasound monitoring in high-risk pregnancies, with a specialized postnatal care plan established when abnormal findings are detected early, also contributes to improved neonatal outcomes. Delivery at a specialized neonatal intensive care center (delivery at a tertiary center) is recommended.